GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
D

Daewoong Pharma 069620.KS · KRW

Health Care · KRX · 🇰🇷 South Korea

Compare

101,600

-1.55%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩1.57trn

FY2016FY2025

Net income

₩195.86bn

FY2016FY2025

Free cash flow

−₩92.16bn

FY2016FY2025

Shareholders' equity

₩1.01trn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue₩1.57trn₩1.42trn₩1.38trn₩1.28trn₩1.15trn₩1.06trn₩1.11trn₩1.03trn₩960.31bn₩883.92bn
Gross profit₩822.53bn₩734.17bn₩688.17bn₩638.96bn₩544.75bn₩446.94bn₩478.29bn₩409.94bn₩406.98bn₩373.69bn
Research and development₩180.31bn₩171.29bn₩171.57bn₩163.60bn₩127.27bn₩115.22bn₩109.44bn₩113.81bn₩107.94bn₩103.69bn
Operating income₩196.78bn₩58.44bn₩122.59bn₩95.80bn₩88.90bn₩16.98bn₩44.69bn₩24.57bn₩38.96bn₩25.89bn
Net income₩195.86bn₩24.73bn₩121.74bn₩42.24bn₩24.66bn₩12.75bn₩22.01bn−₩15.15bn₩31.58bn₩26.97bn
Diluted earnings per share18,976.602,396.5511,795.364,092.622,389.421,235.692,132.17-1,468.072,906.902,907.14

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets₩2.36trn₩1.98trn₩1.57trn₩1.56trn₩1.42trn₩1.37trn₩1.25trn₩1.21trn₩1.21trn₩1.14trn
Total liabilities₩1.23trn₩1.05trn₩762.77bn₩822.12bn₩712.77bn₩671.66bn₩609.75bn₩600.04bn₩581.99bn₩540.15bn
Debt₩550.56bn₩324.48bn₩65.00bn₩204.84bn₩181.71bn₩291.17bn₩388.53bn₩386.85bn₩385.06bn₩396.92bn
Shareholders' equity₩1.01trn₩794.64bn₩802.97bn₩608.02bn₩573.57bn₩550.99bn₩519.31bn₩494.13bn₩519.44bn₩499.49bn
Shares outstanding10m10m10m10m10m10m10m10m11m9m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations₩149.21bn₩51.49bn₩132.57bn₩118.21bn₩39.99bn₩100.98bn₩57.60bn₩47.50bn₩103.94bn₩15.38bn
Capital spending−₩241.37bn−₩229.00bn−₩118.67bn−₩65.23bn−₩29.09bn−₩26.49bn−₩22.31bn−₩56.99bn−₩69.12bn−₩163.25bn
Free cash flow−₩92.16bn−₩177.51bn₩13.89bn₩52.99bn₩10.91bn₩74.50bn₩35.29bn−₩9.49bn₩34.81bn−₩147.87bn
Dividends paid−₩8.08bn−₩7.74bn−₩6.64bn−₩8.07bn−₩6.46bn−₩6.19bn−₩6.19bn−₩6.19bn−₩6.19bn−₩7.22bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₩448.46bn₩377.80bn₩397.12bn₩411.83bn₩405.45bn₩356.49bn₩367.88bn₩358.47bn
Gross profit₩249.08bn₩181.19bn₩210.37bn₩214.00bn₩215.08bn₩183.08bn₩189.69bn₩182.25bn
Operating income₩68.07bn₩36.10bn₩71.38bn₩56.89bn₩53.15bn₩38.70bn₩38.69bn₩37.28bn
Net income₩33.37bn₩25.90bn₩89.84bn₩46.37bn₩37.76bn₩21.89bn−₩12.83bn₩28.28bn
Diluted earnings per share3,232.912,509.578,704.654,492.383,658.192,121.38-1,243.172,740.05
Cash from operations₩47.05bn₩17.21bn₩40.35bn₩57.53bn₩48.24bn₩3.08bn₩22.59bn₩22.21bn
Capital spending−₩67.19bn−₩94.81bn−₩101.43bn−₩72.21bn−₩37.43bn−₩30.29bn−₩73.30bn−₩44.83bn
Free cash flow−₩20.14bn−₩77.60bn−₩61.09bn−₩14.68bn₩10.81bn−₩27.21bn−₩50.72bn−₩22.62bn
Total assets₩2.54trn₩2.45trn₩2.36trn₩2.26trn₩2.11trn₩1.99trn₩1.98trn₩1.92trn
Debt₩397.07bn₩550.82bn₩550.56bn₩481.49bn₩420.50bn₩373.85bn₩324.48bn₩337.34bn
Shareholders' equity₩1.06trn₩1.03trn₩1.01trn₩879.85bn₩831.64bn₩804.24bn₩794.64bn₩817.34bn

Growth per year

Compound annual rate

3 years5 years10 years
Revenue7.1%8.3%6.5%
Operating income27.1%63.2%16.3%
Net income66.8%72.7%16.4%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin52.0%51.1%49.3%46.1%
Operating margin8.5%8.4%7.4%6.0%
Net margin7.4%6.8%5.4%4.2%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings9.152.79.938.761.9133.564.5-128.456.623.6
Price to sales1.10.90.91.31.31.61.31.91.90.7

Dividends and splits

Per share, in the currency the company pays

Paid for 23 years. Last went ex-dividend on 29 Dec 2025.

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Paid in the year1,200.00600.00600.00600.00600.00600.00600.00600.00
  • 1.03-for-1 split · 27 Dec 2012
  • 1.03-for-1 split · 28 Dec 2011
  • 1.03-for-1 split · 29 Dec 2010
  • 1.03-for-1 split · 31 Mar 2010
  • 1.03-for-1 split · 31 Mar 2009
  • 1.03-for-1 split · 31 Mar 2008

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.